Tag: contact information

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Semler Scientific, Inc. (NASDAQ: SMLR) resulting from allegations that Semler Scientific may have issued materially misleading business information to the investing public.

Dubai, July 2, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON”), announces today that it has completed the pricing of a private placement of USD 200 million of senior unsecured notes due in 2029 with institutional investors (the “Notes”), following its announcement on June 16, 2025 that it is considering options to raise external financing through a private placement.

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Laser Photonics Corporation (“Laser Photonics” or the “Company”) (NASDAQ:LASE) on behalf of Laser Photonics stockholders. Our investigation concerns whether Laser Photonics has violated the federal securities laws and/or engaged in other unlawful business practices.

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sable Offshore Corp. (NYSE: SOC), including those who purchased shares pursuant to Sable Offshore Corp.’s May 2025 public offering, resulting from allegations that Sable Offshore Corp. may have issued materially misleading business information to the investing public.

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GoHealth, Inc. (NASDAQ: GOCO) resulting from allegations that GoHealth may have issued materially misleading business information to the investing public.

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline.

Support Development of Dogecoin-Related Tools and Infrastructure

LAS VEGAS, July 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) ("GTV" or the "Company") is pleased to announce the completion of a significant restructuring of its legacy debt obligations and capital structure. The Company has now executed a definitive agreement with a third-party investor who has acquired all outstanding notes previously held by its largest creditor, T&K Zarro, LLC. This strategic investor has expressed strong alignment with the Company's long-term vision and is committed to supporting its continued growth.

As part of the transaction, Golden Triangle Ventures and T&K Zarro, LLC have executed and closed an agreement transferring five outstanding debt instruments—representing more than $7 million in total obligations—to the new private investor. The closing was subject to several corporate actions, including an increase in the Company’s authorized share capital. In connection with the transaction, GTVH secured a fixed price repurchase right from the new investor, granting the Company the exclusive option to reacquire the full balance of the notes, at any time, for a total of $4 million. This represents a significant discount and provides a pathway to eliminate the debt under favorable terms.

LAUSANNE, Switzerland and COPENHAGEN, Denmark, July 01, 2025 (GLOBE NEWSWIRE) -- ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that the first participant has been included in the company’s Phase 2 clinical trial of its lead candidate RPN-001 (leflutrozole), an orally administered aromatase inhibitor in development for the treatment of male infertility (https://clinicaltrials.gov/study/NCT06993155?term=Leflutrozole&rank=1).